Table 2 Most frequent genomic aberrations (>20%) in 28 estrogen receptor-positive invasive ductal carcinomas
Gain (core*) | Frequency (%)†| Loss (core) | Frequency (%) |
|---|---|---|---|
1q21.1-q44 (q32.1) | 50.0–71.4 | 6q11.1-q27 (q14.1-16.3) | 28.6–42.9 |
17q23.2-q25.3 (q23.3) | 57.1–67.9 | 11q13.5-q24.3 (q21-24.3) | 21.4–42.9 |
8q11.21-q24.3 (q24.11) | 42.9–64.3 | 13q12.11-q33.3 (q13.2-14.3) | 25.0-39.3 |
17q12-q22 (q12-21.1) | 35.7–53.6 | 1p32.3-p13.3 (p22.3-21.1) | 21.4–32.1 |
8p12-p11.1 (p11.21) | 35.7–42.9 | 4q12-q35.2 (q13.1-34.3) | 21.4–32.1 |
19p13.3-p13.11 (p13.12-13.11) | 35.7–39.3 | 22q11.21-q12.3 (q11.21) | 25.0–32.1 |
19q12-q13.42 (q12-13.2) | 35.7–39.3 | 3p21.1-p13 (p14.3-14.1) | 21.4–28.6 |
20q11.21-q13.33 (q13.13-13.32) | 25.0–39.3 | 4p15.32-4p12 | 28.6 |
5p15.33 | 35.7 | 6p12.3-p11.2 (p12.3) | 25.0–28.6 |
16p13.3-p11.2 | 35.7 | 9p24.3-p21.2 (p22.3-21.2) | 21.4–28.6 |
3q24-q29 (q29) | 21.4–32.1 | 5q21.2-q21.3 | 25.0 |
22q11.21-q13.33 (q11.21) | 21.4–32.1 | 8p23.2-p21.1 (8p22-21.1) | 21.4-25.0 |
1p36.33-p35.3 (1p36.33) | 21.4–28.6 | 11p15.5-p15.2 (p15.4-15.2) | 21.4-25.0 |
9q33.3-q34.3 (q34.11-34.3) | 25.0–28.6 | 11p11.2-p11.12 | 25.0 |
20p11.22-p11.21 (p11.21) | 25.0–28.6 | 14q24.3-q31.3 (q31.1-31.3) | 21.4–25.0 |
11q13.3 | 25.0–28.6 | 10q23.31-q25.3 | 21.4 |
1p35.3 | 25.0 | 17p13.3-p11.2 | 21.4 |
5p15.32-p12 (p13.2-13.1) | 21.4–25.0 | 22q13.2-13.33 | 21.4 |
13q34 | 25.0 | Â | Â |
16q24.3 | 25.0 | Â | Â |
3q12.1-q13.33 | 21.4 | Â | Â |
7q22.1 | 21.4 | Â | Â |
7q36.3 | 21.4 | Â | Â |
17p11.2 | 21.4 | Â | Â |